Longeveron Inc Stock Price, News & Analysis

Longeveron Inc. (NASDAQ: LGVN) announced that Chris Min, M.D., Ph.D., its Interim CEO and Chief Medical Officer, will present at the Dawson James Small Cap Growth Conference in Jupiter, Florida, on October 12, 2022. The presentation is scheduled for 4:30 – 4:55 p.m. ET, with a live webcast available on the company's website. Longeveron focuses on developing regenerative medicines, notably Lomecel-B™, which targets Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and Aging Frailty.

Longeveron Inc. (NASDAQ: LGVN) appointed Jerome Bailey as vice president of business operations, bringing over 30 years of biopharmaceutical experience. Previously at Checkmate Pharmaceuticals, Bailey managed clinical trials across multiple therapeutic areas. CEO Chris Min highlighted Bailey's expertise as crucial for advancing their lead product, Lomecel-B™, through ongoing Phase 2 trials for Alzheimer’s and Hypoplastic Left Heart Syndrome, with a new trial in Japan on the horizon. Longeveron focuses on regenerative medicines for unmet medical needs.

Longeveron Inc. (NASDAQ: LGVN) announced that Dr. Chris Min, Interim CEO and Chief Medical Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York City from September 12-14, 2022. The presentation is scheduled for September 13, 2022, from 8:30 to 9:00 a.m. ET. Interested parties can access the live webcast on Longeveron's website, with a replay available for 90 days. Longeveron focuses on cellular therapies for aging-related and life-threatening conditions, currently conducting Phase 1 and 2 clinical trials for various indications.

Longeveron Inc. (NASDAQ: LGVN) has received Fast Track Designation from the FDA for its investigational therapy Lomecel-B™. This therapy aims to treat Hypoplastic Left Heart Syndrome (HLHS), a rare congenital defect affecting about 1,000 infants annually in the U.S. Lomecel-B™ is currently undergoing a Phase 2a clinical trial. Fast Track Designation enhances interactions with the FDA, potentially accelerating approval. Notably, the ELPIS Phase 1 trial indicated 100% survival rate without heart transplants among participants.

Longeveron Inc. (NASDAQ: LGVN) announced the European Patent Office's intent to grant a patent for methods treating endothelial dysfunction with its cell therapy, Lomecel-B™. This patent, which focuses on monitoring efficacy through Vascular Endothelial Growth Factor (VEGF), reinforces Longeveron's intellectual property. The company aims to address various aging-related conditions and has received Rare Pediatric Disease Designation and Orphan Drug Designation for Lomecel-B™ targeting Hypoplastic Left Heart Syndrome. The patent is expected to expire in November 2035.

Longeveron (NASDAQ: LGVN) announced progress in its clinical trials, including a Phase 2a trial for Lomecel-B in Alzheimer’s patients, with 50% enrollment achieved. The Japanese PMDA accepted an amended trial design for Aging Frailty, potentially allowing accelerated market entry. The Phase 1/2 HERA trial noted met safety endpoints, showing promise for Lomecel-B. Financially, the company reported $27 million in cash as of June 30, 2022, sufficient to fund operations into 2024, although net losses increased to $5.6 million from $5 million year-over-year.

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology firm, announced that an abstract detailing the Phase 2a trial of Lomecel-B in Alzheimer’s Disease has been accepted for presentation at the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022. Ongoing enrollment for the trial is noted. Earlier in 2022, a peer-reviewed study confirmed the success of Lomecel-B in a Phase 1b trial, achieving its primary endpoint with good tolerability in patients. The poster presentation is scheduled for August 2, 2022.

Longeveron Inc. (NASDAQ: LGVN) reported its Q1 2022 financial results, highlighting a revenue of $0.4 million, consistent with Q1 2021. Clinical trial revenue increased by 88% to $0.3 million due to reduced COVID-19 travel restrictions, while grant revenue fell 72% to $0.1 million due to the completion of prior trials. R&D expenses rose by 6% to $1.4 million, and G&A expenses increased by 16% to $2.0 million, leading to a net loss of $3.5 million. Cash and short-term investments stood at $30.6 million. The company anticipates sufficient funds to cover expenses into H1 2024.

Longeveron Inc. (NASDAQ: LGVN) announced the resignation of CEO Geoff Green, effective June 1, 2022. K. Chris Min, M.D., Ph.D., the current Chief Medical Officer, will serve as Interim CEO while a nationwide search for a permanent successor takes place. Under Green's leadership, Longeveron progressed significantly, advancing their Lomecel-B therapy into clinical trials. The company specializes in cellular therapies targeting aging-related and life-threatening conditions and is pursuing Phase 1 and 2 trials for multiple indications including Alzheimer’s disease and frailty.